About HLHIX
Virtus KAR Health Sciences Fund Institutional Class is a mutual fund specializing in investments across the healthcare sector, including pharmaceuticals, biotechnology, and medical device companies. The fund’s core objective is to achieve attractive long-term competitive returns by investing in companies that deliver innovative and cost-effective healthcare solutions. It employs a high-conviction, quality-focused approach, selecting firms with strong financials, consistent growth records, and dominant market positions. Portfolio construction is influenced by themes like biotechnology breakthroughs, preventive care, and advancements in health-related technologies, while also applying rigorous valuation and ESG risk criteria.
Managed by Kayne Anderson Rudnick Investment Management, the fund typically holds 40–50 stocks, with a notable concentration in its top ten holdings, often totaling over half its assets. It maintains a large-blend investment style and a significant allocation to large-cap healthcare leaders such as Eli Lilly, AbbVie, and UnitedHealth Group. The fund specifically aims to capitalize on structural tailwinds, such as demographic shifts toward an aging population and the ongoing rise in global healthcare expenditures. It is designed for institutional investors, requiring a $1,000,000 minimum investment and charging an expense ratio above the peer group median.
Fund Family Virtus
Category Health
Performance Rating Average
Risk Rating Average
Stock Exchange Nasdaq
Ticker Symbol HLHIX
Share Class Institutional Class
Index MSCI World/Health Care NR
HLHIX had a total return of 14.15% in the past year, including dividends. Since the fund's
inception, the average annual return has been 7.39%.
